Europe (WHO region) vs Tuvalu: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Tuvalu
100.0%
in 2021
Europe (WHO region) rank
2nd
Tuvalu rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Tuvalu
How they compare
Tuvalu currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Tuvalu's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 1 time across 6 shared years of data; in 2014 it was Europe (WHO region) ahead.
Europe (WHO region) ranks 2nd and Tuvalu ranks 1st of 11 groups.
Across the 2 decades both report, Europe (WHO region) averaged higher in 1 and Tuvalu in 1.
Head to head by decade
| Decade | Europe (WHO region) | Tuvalu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 75.5% | 36.8% | 38.8% | Europe (WHO region) |
| 2020s | 94.5% | 100.0% | 5.5% | Tuvalu |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Tuvalu?
- Tuvalu, at 100.0% against 90.0% in Europe (WHO region) as of 2021.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Tuvalu?
- 10.0%, with Tuvalu ahead.
- How many years of comparable data are there for Europe (WHO region) and Tuvalu?
- 6 years are reported by both, from 2014 to 2021.
- How do Europe (WHO region) and Tuvalu rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Tuvalu ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.